NCT04596488View on ClinicalTrials.gov

Efavirenz 400mg in Treatment-naïve Chinese HIV-infected Patients

NACompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

June 1, 2017

Primary Completion Date

December 30, 2018

Study Completion Date

December 30, 2019

Conditions
HIV-1-infection
Interventions
DRUG

Efavirenz 400mg

HIV-infected patients were treated with efavirenz 400mg combined with tenofovir 300mg and lamivudine 300mg.

Trial Locations (1)

100730

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
collaborator

National Key Technologies R&D Program for the 13th Five-year Plan

UNKNOWN

collaborator

National Key Technologies R&D Program for the 12th Five-year Plan

UNKNOWN

collaborator

CAMS Initiative for Innovative Medicine

UNKNOWN

lead

Peking Union Medical College Hospital

OTHER

NCT04596488 - Efavirenz 400mg in Treatment-naïve Chinese HIV-infected Patients | Biotech Hunter | Biotech Hunter